Company Information

  

Address: 7020 KIT CREEK ROAD
SUITE 270 
City: RESEARCH TRIANGLE PARK 
State: NC 
Zip Code: 27709 
Telephone: 919-313-9650 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Our stated objective is to build a major ophthalmic pharmaceutical company and our strategy is to advance our product candidates, including Rhopressa(TM) (netarsudil ophthalmic solution) 0.02% ("RhopressaTM"), and Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% ("RoclatanTM"), to regulatory approval and commercialize these products ourselves in North American markets. If approved, we plan to build a commercial team of approximately 100 sales representatives to target approximately 10,000 high prescribing eye-care professionals throughout the United States. Our strategy includes developing our business outside of North America, including obtaining regulatory approval on our own for our product candidates in Europe and Japan.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-3.26NAN/E
03/2017-3.31NAN/E
12/2016-3.40NAN/E
09/2016-3.28NAN/E
06/2016-3.17NAN/E
03/2016-3.03NAN/E
12/2015-2.88NAN/E
09/2015-2.80NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.23Total Liab/Total Assets0.58
Net Inc/Total Assets-0.40Total Liab/Inv Cap0.62
Net Inc/Inv Cap-0.43Total Liab/Comm Equity0.34
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/Equity1.17
SG&A/NetSalesNATotal Debt/Equity1.17
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio12.27
Inventory TurnoverNACurrent Ratio12.27
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 17.15 14.48 14.66 10.63
Operating Income -27.77 -25.43 -28.76 -23.32
Interest Exp NA NA NA NA
Pretax Income -28.39 -25.74 -29.26 -23.78
Other Income -0.62 -0.31 -0.50 -0.46
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -28.43 -25.79 -29.32 -23.81

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 307.92 207.86 233.66 253.63
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 309.98 210.22 237.69 256.54
Net Property, Plant & Equipment 14.39 12.53 7.86 4.61
Total Assets 326.98 225.41 248.25 265.92
Liabilities        
Accounts Payable 13.81 13.56 19.37 14.10
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 13.81 13.56 19.37 14.10
Long-Term Debt 123.69 123.62 123.54 123.46
Total Liabilities 141.94 141.29 142.91 137.56
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.04 0.03 0.03 0.03
Retained Earnings -370.84 -342.41 -316.62 -287.30
Treasury Stock NA NA NA NA
Total Stockholders' Equity 185.04 84.12 105.34 128.36
Total Liabilities and Stockholders' Equity 326.98 225.41 248.25 265.92

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -20.93 -24.85 -18.85 -21.16
Net Cash Provided by Investing Activities 1.39 -33.61 4.09 8.89
Net Cash Provided by Financing Activities 122.66 0.05 0.77 165.69

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-14.98--
12/20130.00-31.15-6.38
12/20140.00-48.13-2.00
12/20150.00-74.36-2.88
12/20160.00-99.06-3.40
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1719734,53795.04




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.